Brind.

Enveda announced milestones from Boulder, Colo., securing Series D funding from Baillie Gifford and welcoming Mikael Dolsten to its Board of Directors.

1 report, 1 independent Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Enveda announced milestones from Boulder, Colo., securing Series D funding from Baillie Gifford and welcoming Mikael Dolsten to its Board of Directors.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

  • Enveda

    Biotechnology Company in Boulder (CO)

    Nothing else this week.

  • Mikael Dolsten

    Swedish-American doctor, business executive & corporate director; Chief Scientific Officer, Pfizer

    Nothing else this week.

  • Baillie Gifford

    investment management firm

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • Business WireEnveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors Pipeline expansion: Company advances first-in-class